Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05553145 · ClinicalTrials.gov registry record
The Prevalence of Autoimmune Antibodies in Patients with Type 2 Diabetes Managed by Endocrinology Vs. Primary Care
A clinical trial, sponsored by The Cleveland Clinic.
- Completed
- Registry status
- 200
- Enrollment target
NCT05553145: Completed study, sponsored by The Cleveland Clinic.
NCT05553145 is a clinical trial that has completed, run by The Cleveland Clinic. The registered enrollment target is 200 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05553145 has completed, sponsored by The Cleveland Clinic.
- COMPLETED
- Registry status
- 200 participants
- Enrollment target
Study Summary
The purpose of this study is to assess the levels of autoimmune markers of diabetes in those with a type 2 diabetes diagnosis.
Primary Outcome
Percentage of subjects with T2D and detectable autoimmune antibodies calculated as the percentage of subjects that test positive for at least one of the autoimmune antibodies
Interventions
- DIAGNOSTIC_TEST Autoimmune Antibody Assays
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 200 participants |
| Start Date | 2022-09-01 |
| Est. Completion | 2024-08-29 |
What the finished NCT05553145 record still lists
NCT05553145 is an observational study that tracks outcomes without assigning an intervention. The registered 200 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 1 intervention - of which Autoimmune Antibody Assays is the first listed.
NCT05553145 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05553145 about?
NCT05553145 is a clinical study titled "The Prevalence of Autoimmune Antibodies in Patients with Type 2 Diabetes Managed by Endocrinology Vs. Primary Care". The purpose of this study is to assess the levels of autoimmune markers of diabetes in those with a type 2 diabetes diagnosis.
What is the current status of trial NCT05553145?
This trial is currently completed. The enrollment target is 200 participants. The study started on 2022-09-01. Estimated completion is 2024-08-29.
What interventions are being tested in trial NCT05553145?
The interventions under investigation include: Autoimmune Antibody Assays (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT05553145?
This trial is sponsored by The Cleveland Clinic, which has 688 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00107289 · 200 participants · Phase 2
Iodine I 131 Metaiodobenzylguanidine in Treating Patients With Recurrent, Progressive, or Refractory Neuroblastoma or Malignant Pheochromocytoma or Paraganglioma
- NCT00109174 · 200 participants · NA
MRS Measurement of Glutamate and GABA Metabolism in Brain
- NCT00177268 · 200 participants
Blood, Urine, and Tissue Collection for Cutaneous Lymphoma, Eczema, and Atopic Dermatitis Research
- NCT00493688 · 200 participants
A Study to Determine Whether Perioperative Energy Dynamics Correlates With Postoperative Outcomes
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI